Alzheimer’s Disease
Conditions
Interventions
normal control:data collection and follow-up
Subjective cognitive decline:data collection and follow-up
mild cognitive impairment:data collection and follow-up
Alzheimers disease:data collection and follow-up
Sponsors
Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing
Eligibility
Sex/Gender
All
Age
50 Years to 90 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria for subjective cognitive decline: (1) A persistent decline in perceived cognitive ability compared to normal in the past, not associated with any acute event; 2. Subjective cognitive decline in the last 5 years, onset age =60 years; 3. Cognitive function decline was confirmed by informed participants; 4. Normal performance on standard cognitive tests adjusted for age, sex, and years of education; Clinical diagnostic criteria for mild cognitive impairment: 1. Cognitive impairment reported by patients or informed persons, or discovered by experienced clinicians; 2. There is objective evidence of impairment in one or more cognitive domains (neuropsychological tests), of which episodic memory impairment is the most common; 3. Complex instrumental daily abilities may be slightly impaired, but the ability to maintain independent daily living; 4. The diagnostic criteria for dementia have not been met. Inclusion criteria for AD-derived MCI: 1. MCI clinical diagnostic criteria + AD-related markers: 1. If the Aß biomarker is positive, and the biomarker of neuronal damage is also positive, then the subject's MCI is likely to be AD-derived MCI; 2. If the biomarker of neuronal damage is undetected or undetectable but the Aß biomarker is positive, or if the biomarker of Aß is undetected or undetectable but the biomarker of neuronal damage is positive, then the likelihood of the subject having AD-derived MCI is medium; 3. If both the biological markers of Aß and neuronal damage are negative, then it is unlikely Ad-derived MCI; 4. If biomarkers of both Aß and neuronal damage are not detected, or if the results are not clear, then no judgment can be made based on the biomarker. When pathological, humoral, or molecular imaging (PET) markers cannot be detected, MCI from other sources (MCI related to Parkinson's disease, vascular disease, lewy body disease, autoimmune encephalopathy, etc.) should be excluded through identification of clinical neuropsychological characteristics and imaging data. Patients with MCI who meet the neuropsychological cognitive impairment characteristics of AD-derived MCI (such as hippocampal amnesia disorder syndrome) and cranial MRI imaging characteristics can be diagnosed with "AD-derived MCI" at the clinical level. Diagnostic criteria for Alzheimer's disease: 1. Clinical evaluation 1. Cognitive assessment 1.1 Comprehensive cognitive assessment The dementia criteria adjusted according to the education level of the mini-mental state examination (MMSE) were: illiterate, primary school, secondary school, college, =22 points, =23 points, =24 points, =26 points; The Montreal Cognitive Assessment (MoCA) defines the threshold for dementia as =18 points, with a score plus one point for =12 years of schooling; 1.2 Single-domain cognitive assessment 1.2.1 Criteria for memory dysfunction: Long delayed AVLT recall, =4 in 50-59 years old, =3 in 60-69 years old, =2 in 70-79 years old as abnormal; 1.2.2 Language dysfunction: Chinese version of Boston Naming Test-30 (BNT-30), AD dementia: =21.5 points; Controlled Verbal word Association Test (COWAT), AD dementia: < 26; 1.2.3 Visual Spatial Dysfunction: Chinese Version of Connection test-A (MTT-A) : AD dementia, =98.5s; 1.2.4 Executive dysfunction: Chinese version Connection test-B (MTT-B) : AD dementia, =188.5s. 2. Behavior assessment Neuropsychiatric questionnaire (NPI) =8.0 score; Behavioral disorders or psychobehavioral symptoms associated with AD were assessed with a sco
Exclusion criteria
Exclusion criteria: 1. Mild cognitive impairment (MCI) or Alzheimer's disease (AD) prodromal stage or dementia; 2. Symptoms of cognitive decline can be explained by psychiatric or neurological disorders (other than AD), medical disorders, or drug or other substance use.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Clinical symptom;Neuropsychological assessment;imaging data; | — |
Countries
China
Contacts
Public ContactYUN XU
Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing
Outcome results
None listed